A
Aminah Jatoi
Researcher at Mayo Clinic
Publications - 440
Citations - 15796
Aminah Jatoi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 46, co-authored 404 publications receiving 12708 citations. Previous affiliations of Aminah Jatoi include University of Texas Health Science Center at San Antonio & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).
Aminah Jatoi,Shaker R. Dakhil,Jeff A. Sloan,John W. Kugler,Kendrith M. Rowland,Paul L. Schaefer,Paul J. Novotny,Donald B. Wender,Howard M. Gross,Charles L. Loprinzi +9 more
TL;DR: Although previous studies suggest otherwise, this randomized, double-blinded, placebo-controlled study did not find that tetracycline lessened rash incidence or severity in patients who were taking EGFR inhibitors.
Journal ArticleDOI
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
Karin F. Giordano,Aminah Jatoi,P. J. Stella,Nathan R. Foster,Loren K. Tschetter,Steven R. Alberts,S. R. Dakhil,James A. Mailliard,Patrick J. Flynn,Daniel A. Nikcevich +9 more
TL;DR: The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction and merits further study.
Journal ArticleDOI
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.
Steven E. Schild,Sumithra J. Mandrekar,Aminah Jatoi,William L. McGinnis,P. J. Stella,Richard L. Deming,James R. Jett,Yolanda I. Garces,Katie L. Allen,Alex A. Adjei +9 more
TL;DR: The objective of this study was to assess the value of combined‐modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who receive RT plus chemotherapy for stage III nonsmall cell lung cancer (NSCLC).
Journal ArticleDOI
Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers.
Faye R. Harris,Irina V. Kovtun,James B. Smadbeck,Francesco Multinu,Aminah Jatoi,Farhad Kosari,Kimberly R. Kalli,Stephen J. Murphy,Geoffrey C. Halling,Sarah H. Johnson,Minetta C. Liu,Andrea Mariani,George Vasmatzis +12 more
TL;DR: A panel of individualized junctions derived from tumor DNA could be an effective way to monitor cancer patients for relapse and therapeutic efficacy using cfDNA.
Journal ArticleDOI
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Hyman B. Muss,Mei Yin C. Polley,Donald A. Berry,Heshan Liu,C. Cirrincione,Maria Theodoulou,Ann M. Mauer,Alice B. Kornblith,Ann H. Partridge,Lynn G. Dressler,Harvey J. Cohen,Patricia A. Kartcheske,Edith A. Perez,Antonio C. Wolff,Julie R. Gralow,Harold J. Burstein,Ahmad A. Mahmood,Linda Sutton,Gustav Magrinat,Barbara A. Parker,Ronald D. Hart,Debjani Grenier,Arti Hurria,Aminah Jatoi,Larry Norton,Clifford A. Hudis,Eric P. Winer,Lisa A. Carey +27 more
TL;DR: With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor-negative disease, andCompeting risks in this older population dilute overall survival benefits.